BioXcel Therapeutics Inc. (BTAI) is expected to release topline data from its phase III trial evaluating the safety of a 120-mcg dose of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting, dubbed SERENITY At-Home, this month. The stock leads premarket gainers today on growing investor anticipation.
The following is the list of biotech stocks making big moves in premarket hours.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.